October 8, 2021 - Crown Bioscience, a JSR Life Sciences Company, announced the launch of its '3D Ex Vivo Patient Tissue Platform' to improve predictability of immuno-oncology drug candidates.

For more information on Crown Bioscience's 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscience's webpage on the new service.
Link to PR https://blog.crownbio.com/press/crown-bioscience-launches-3d-ex-vivo-patient-tissue-platform

Attachments

  • Original document
  • Permalink

Disclaimer

JSR Corporation published this content on 08 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 October 2021 06:06:03 UTC.